Another step toward final call on Remdesivir efficacy as a treatment for hospitalized COVID-19 patients: a multicenter open-label trial

Abstract: medRxiv preprint doi: https://doi.org/10.1101/2021.08.13.21261992; this version posted August 13, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license . Title: Another step toward final call on Remdesivir efficacy as a treatment for hospitalized COVID-19 patients: a multicenter open-label trial Running title: Remdesivir efficacy in COVID-19 treatment Authors: Hamed Hosseini1, Anahita Sadeghi2, Payam Tabarsi3, Azin Etemadimanesh4, Ilad Alavi Darazam3, Nasser Aghdami4, Saeed Kalantari5, Mehrdad Hasibi4, Azar Hadadi4, Farhang Babamahmoodi6, Mansooreh Momen-Heravi7, Ahmad Hormati8,9, Yunes Panahi10, Rozita Khodashahi11, Mohammadreza Salehi4* 1. Center for Research and Training in Skin Disease and Leprosy, Tehran University of Medical Sciences. 2. Department of Internal Medicine, Tehran University of Medical Sciences, Tehran, Iran. 3. Department of Infectious Disease, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 4. Department of Infectious Disease, Tehran University of Medical Science, Tehran, Iran. 5. Antimicrobial Resistance Research Center, Iran University of Medical Sciences, Tehran, Iran 6. Antimicrobial Resistance Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran 7. Department of infectious diseases, faculty of medicine, Kashan university of medical sciences, Kashan, Iran. 8. Gastroenterology and Hepatology Disease Research Center, Oom university of medical sciences, Iran. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2021.08.13.21261992; this version posted August 13, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license . 9. Gastrointestinal and Liver Diseases Research Center, Iran university of medical sciences, Tehran, Iran. 10. Pharmacotherapy Department, Faculty of Pharmacy, Baqiyatallah University of Medical Sciences, Tehran, Iran 11. Department of Infectious disease and tropical medicine, Faculty of Medicine, Mashhad university of medical sciences, Mashhad, Iran. Corresponding author: Mohammadreza Salehi M.D., Department of Infectious Disease, Tehran University of Medical Sciences. Imam Khomeini hospital complex, Gharib St., Tehran, Iran. Email: salehi.mohamad3@gmail.com , ORCID: 0000-0002-1987-5929, Cellphone: +989123159842 Declaration of interests: Hereby, all authors of this study declare no conflict of interests before, during, and after the study was done. Acknowledgments: Our sincere thanks to Professor Reza Malekzadeh who coordinated and supervised the project. We express our gratitude to the Digestive Diseases Research Institute (DDRI), Tehran University of Medical Sciences. Conducting the study would not have been possible without the efforts of the DDRI team. The authors also would like to express their gratitude for all care workers and patients in study hospitals. This study has been funded and supported by Tehran University of Medical Sciences (TUMS); Grant no. 99-1-97-47143. medRxiv preprint doi:..